- Lung Cancer Basics
Thursday, September 14, 2017 – Today, U.S. Food and Drug Administration (FDA) approved Mvasi (bevacizumab-awwb, Amgen Inc.) as a biosimilar to Avastin (bevacizumab, Genentech Inc.). Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer. It has been approved for a number of cancers including non-squamous non-small cell lung cancer, in combination with chemotherapy for first line treatment of advanced cancer that cannot be removed by surgery.
Biosimilars are a type of drug approved by FDA because they are highly similar to an already FDA-approved drug and have been shown to have no clinically meaningful differences.